Chinese military unveils mosquito-sized drones that can perform battlefield missions
The drone's main unique selling point is its compact size, making it relatively easy to hide or conceal. It has two leaflike wings that are reportedly able to flap just like an insect's wings.
'Here in my hand is a mosquito-like type of robot. Miniature bionic robots like this one are especially suited to information reconnaissance and special missions on the battlefield,' Liang Hexiang, a student at NUDT, told CCTV while holding up the drone between his fingers.
The drone also has three hair-thin "legs" that could be used for perching or landing. Dinky drones of this kind could likely be used in urban combat, search and rescue, or electronic surveillance.
It could also be a valuable tool for reconnaissance and covert special missions. To make it work, the drone features advanced integration of power systems, control electronics, and sensors, all in an incredibly tiny package.
These drones can operate undetected, making them valuable in covert warfare, espionage, or tactical reconnaissance. However, given their size, they are pretty challenging to design and build.
Engineering at that scale is challenging, particularly with components such as batteries, communications, and sensors that must be miniaturized without sacrificing functionality.
https://www.youtube.com/watch?v=x19eT9O9WHU&pp=ygUXTm9yd2F5ICBCbGFjayBIb3JuZXQgNCw%3D
Its development may also signal a broader trend. For example, the U.S., Norway, and other countries are also investing in micro-UAVs for both military and non-military purposes.
Norway's "Black Hornet" is a prime example. This palm-sized device is in service with many Western militaries and is used for close-range scouting. The latest version, "Black Hornet 4," has improved durability and range.
Developed by Teledyne FLIR Defence, this drone won the 2025 US Department of Defence Blue UAS Refresh award, which recognises unmanned aerial systems. The model's enhanced battery life, weather resilience, and communication range address common challenges faced by microdrone developers.
Harvard has also previously unveiled its RoboBee micro-UAV. Similarly powered using flapping "wings," this drone can fly, land, and even transition from water to air.
In 2021, the US Air Force confirmed that it was developing tiny drones. However, there have been no updates regarding any completed technology or deployment.
Beyond military applications, micro-UAVs like these could have essential roles in other industries. In the medical sciences, for example, similar technologies are being researched for use in surgery, drug delivery, diagnostics, and medical imaging.
It could also be used in applications such as environmental monitoring, where future microdrones could be utilized for pollution tracking, crop monitoring, or disaster response.
Looking at the bigger picture, "microdrones" like these mark a significant step in military micro-robotics, demonstrating that countries like China are advancing rapidly in next-generation surveillance tools.
It also highlights a global race where small, intelligent, and stealthy robots could redefine how both soldiers and scientists interact with the world, whether on a battlefield or inside a human body.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SCG101V, marking the first-ever investigational cell therapy to enter regulatory approved Phase 1/2 clinical trial for chronic hepatitis B virus (HBV) infection. SCG101 is designed to cure chronic hepatitis B by eliminating HBV cccDNA and HBV-DNA integration within HBV-infected hepatocytes, which are the fundamental source of persistent infection and antigen production. These infected hepatocytes serve as the long-term viral reservoir that current antiviral therapies fail to eradicate. "SCG101 is designed to mimic the natural immune response observed in individuals who are able to clear HBV infection spontaneously. HBV-specific T cells play a central role in this process and, remarkably, through genetic engineering of T cells, we were able to replicate this natural process as demonstrated in our preclinical models and clinical data in hepatocellular carcinoma, providing strong evidence that this promise holds true in hepatitis B patients", said Professor Ulrike Protzer, Scientific Founder of SCG Cell Therapy and Director of Institute of Virology Technical University of Munich / Helmholtz Munich. In Phase 1 clinical trial of SCG101 in patients with HBV-related hepatocellular carcinoma (HCC), SCG101 demonstrated a good safety profile and sustained clearance of serum hepatitis B surface antigen (HBsAg), even in heavily pre-treated patients. Among the treated patients, 94% of patients had previously received nucleoside analogue (NA) antiviral therapy, and 72% presented with baseline liver cirrhosis. Following a single infusion of SCG101, all patients experienced a rapid decline in HBsAg level. Notably, 94% achieved a 1.0–4.6 log₁₀ reduction in HBsAg within 28 days, with HBsAg levels remained <100 IU/mL for up to one year without rebound. Furthermore, 23% of patients achieved complete HBsAg loss, a critical benchmark for a cure. Professor Niu Jinqi, Vice President and Chief Physician of The First Hospital of Jilin University, commented: "SCG101 has demonstrated significant breakthrough potential in HBV-related liver cancer, remarkably, achieving HBsAg loss following a single dose. This IND approval by the NMPA marks a pioneering step toward a functional cure for chronic hepatitis B. We are excited about the prospects of this therapy and the benefit it could bring to millions of patients, helping to reduce the burden of liver disease in China and globally". Chronic HBV infection affects an estimated 300 million people globally and is a leading cause of liver cirrhosis and hepatocellular carcinoma, contributing to more than 820,000 deaths each year. While current standard-of-care therapies can suppress viral replication, they rarely achieve a functional cure and therefore cannot fundamentally halt disease progression. "This IND clearance represents a historic milestone—not only for SCG but for the broader field of hepatitis B treatment. With indications across HBV-related hepatocellular carcinoma, HBV-related cholangiocarcinoma, and chronic hepatitis B, this IND clearance further validates our development strategy—expanding from virus-induced cancers to chronic infectious diseases", said Christy Ma, Chief Executive Officer of SCG Cell Therapy. "SCG101 is the first cell therapy product to receive regulatory approval to enter a Phase 1/2 clinical trial specifically for HBV and HBV-induced cancer, and we are proud to lead the way in advancing toward a long-term functional cure. We remain on track for initiation of a pivotal study, following the recent completion of our Phase 1 study in patients with HBV-HCC. We look forward to sharing additional clinical data as we continue to push the boundaries of what's possible in cell therapy." – END – About SCG101 SCG101 is an investigational autologous T cell receptor (TCR) T cell therapy designed to selectively target specific epitope of the hepatitis B surface antigen (HBsAg). Powered by SCG's proprietary GianTCR™ screening platform, which enables the discovery of natural, high-affinity, high-avidity TCRs against intracellular antigens presented via the major histocompatibility complex (MHC). SCG101 delivers precise immune-mediated clearance of infected and malignant cells demonstrating significant tumour inhibition and the eradication of HBV covalently closed circular DNA (cccDNA) in preclinical and clinical studies. About HBV Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection is a major global health issue, affecting nearly 300 million people across the world. Approximately 1.1 million people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options. About SCG Cell Therapy SCG Cell Therapy is a leading biotechnology company dedicated to developing novel immunotherapies for infectious diseases and associated cancers. The company focuses on targeting some of the most common cancer-causing infections, including Helicobacter pylori, HPV, HBV, and EBV. SCG is advancing a broad pipeline of TCR-based therapeutics aimed at preventing and curing infection-related cancers. Headquartered in Singapore, SCG operates across Singapore, China, and Germany, leveraging regional strengths to cover the entire value chain, from innovative drug research and discovery to manufacturing, clinical development, and commercialization. For more information, please visit View original content: SOURCE SCG Cell Therapy Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Murata Launches World's First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks
KYOTO, Japan, July 08, 2025--(BUSINESS WIRE)--Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world's first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata's proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (WLAN) standards such as Wi-Fi 6E and Wi-Fi 7 are expanding into higher frequency domains to accommodate ultra-fast data rates. Filters used in these applications must address key challenges, such as preventing out-of-band interference, maximizing system battery performance, and meeting strict space limitations. Traditional approaches using Low Temperature Co-Fired Ceramic (LTCC) or conventional Bulk Acoustic Wave (BAW) filters often fall short in these performance areas. Murata's new XBAR-based filter addresses these limitations by achieving high attenuation performance while maintaining a wide bandwidth and low signal loss. The XBAR structure itself excites bulk acoustic waves using comb-shaped electrodes and a piezoelectric single-crystal thin film, enabling performance beyond the reach of conventional filter structures. It effectively removes high-frequency interference, even in bands above 3 GHz, allowing for clearer signal detection and better performance, contributing to high-speed, high-capacity, and high-quality wireless communication. Key performance parameters include a passband of 5150–7125 MHz, a typical insertion loss of 2.2 dB, and a typical return loss of 17 dB. Typical attenuation figures are 11 dB at 4800–5000 MHz, 28 dB at 3300–4800 MHz, 27 dB at 7737–8237 MHz, and 26 dB at 10300–14250 MHz. The new filter is targeted at devices with embedded wireless functionality, including smartphones, wearables, notebook PCs, and communication gateways, offering an optimal balance of performance and cost efficiency. Murata will continue to drive innovation in filter technologies to support the evolution of wireless communications, and expects this architecture to scale further, with future product generations capable of operating effectively in ultra-high frequency bands above 10GHz. Notes:*1 According to Murata research as of July 7, 2025.*2 XBAR technology: Murata's proprietary filter structure that excites bulk acoustic waves using comb-shaped electrodes and piezoelectric single-crystal thin films. For inquiries regarding this product, please contact us. About MurataMurata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. View source version on Contacts For more information, please contact:Murata Manufacturing Co., Tsuboi, prsec_mmc@ Corporate Communications Department Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Snapdragon X Elite
TAIPEI, July 7, 2025 /PRNewswire/ -- Advantech is proud to introduce its latest suite of high-performance edge AI compute solutions powered by the Snapdragon® X Elite platform – the AOM-6731, AIMB-293, and SOM-6820. Built on this groundbreaking platform, these innovative products are engineered to meet the demanding requirements of modern industrial applications by delivering exceptional processing power, integrated AI acceleration with up to 45 TOPS of AI performance, and robust and lightning-fast 5G and Wi-Fi 7 connectivity into an industrial PC. The solutions powered by the Snapdragon X Elite 12-core and Snapdragon® X Plus 10-core with a leading Qualcomm Oryoton™ CPUs, reaching speeds of up to 3.4GHz. This high-performance processing not only ensures enables rapid data handling and seamless multitasking but also outperforms traditional x86 solutions—using 28% less power on average for everyday tasks, including Teams video calls, local video playback, web browsing, and Microsoft 365. Enhancing AI capabilities, these devices are integrated with Qualcomm® Hexagon™ NPU, providing up to 45 TOPS. The solutions, which contain Snapdragon X Elite platforms, are equipped with LPDDR5X memory, offering a 1.3× speed boost—from 6400MT/s to 8533MT/s—while cutting power consumption by 20% compared to standard LPDDR5. In addition, the integration of UFS 3.1 Gear 4 storage dramatically increases data transfer speeds from 1,000Mbps (PCIe Gen3 NVMe) to an impressive 16,000Mbps. For even greater durability and shock resistance, UFS 4.0 storage solutions are available, ensuring optimal performance in harsh industrial environments. For multimedia-intensive applications, the integrated Snapdragon Adreno 5th Generation VPU supports 4K60p full-duplex H.264 video encoding/decoding. Additionally, the Adreno GPU—equipped with OpenCL, OpenGL, and Microsoft DirectX 12 support—ensures superior graphics performance for vision-centric tasks. Advantech's products take connectivity to the next level with integrated Wi-Fi 7 and 5G technologies, delivering ultra-fast, low-latency network performance, ensuring uninterrupted data streaming and real-time communication even in the most demanding industrial settings. With Wi-Fi 7's multi-gigabit speeds and enhanced network reliability combined with the expansive coverage and high-speed capabilities of 5G, these solutions support data-intensive AI applications and robust remote operations. The result is a truly agile and future-ready infrastructure that optimizes real-time processing and connectivity, empowering industries to harness the full potential of edge AI in today's fast-paced digital landscape. The AI module AOM-6731, the Mini-ITX motherboard AIMB-293, and the COM Express Type 6 module SOM-6820—will be available for engineering evaluations starting in March 2025. For further details on these models, please visit Advantech website. View original content to download multimedia: SOURCE Advantech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data